世界のアンチセンスオリゴヌクレオチド(ASO)治療市場2021-2031

■ 英語タイトル:Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031

調査会社visiongain社が発行したリサーチレポート(データ管理コード:VGA21MA007)■ 発行会社/調査会社:visiongain
■ 商品コード:VGA21MA007
■ 発行日:2021年3月
■ 調査対象地域:グローバル
■ 産業分野:医薬品
■ ページ数:368
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Sigle User(1名様閲覧用、1年間、印刷不可)USD4,549 ⇒換算¥673,252見積依頼/購入/質問フォーム
Global Site License(法人閲覧用、1年間、印刷可)USD9,099 ⇒換算¥1,346,652見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
visiongain社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界のアンチセンスオリゴヌクレオチド(ASO)治療市場2021-2031]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

本調査レポートでは、世界のアンチセンスオリゴヌクレオチド(ASO)治療の市場について調査・分析し、レポート概要、エグゼクティブサマリー、製品・技術概要、DNA読取・書込・編集の取組、市場動向、治療別(神経筋障害におけるアンチセンスオリゴヌクレオチドベース治療)分析、投与経路別(強化安定化化学ベース送達、ナノ製剤ベース送達、脂質ベース送達システム)分析、種類別(がん、心血管疾患、炎症・自己免疫疾患、神経疾患、感染症)分析、地域別分析、臨床試験における潜在的薬剤候補、主要企業情報などの項目を掲載しています。
・レポート概要
・エグゼクティブサマリー
・製品・技術概要
・DNA読取・書込・編集の取組
・市場動向
・世界のアンチセンスオリゴヌクレオチド(ASO)治療市場規模:治療別(神経筋障害におけるアンチセンスオリゴヌクレオチドベース治療)
・世界のアンチセンスオリゴヌクレオチド(ASO)治療市場規模:投与経路別(強化安定化化学ベース送達、ナノ製剤ベース送達、脂質ベース送達システム)
・世界のアンチセンスオリゴヌクレオチド(ASO)治療市場規模:種類別(がん、心血管疾患、炎症・自己免疫疾患、神経疾患、感染症)
・世界のアンチセンスオリゴヌクレオチド(ASO)治療市場規模:地域別
・臨床試験における潜在的薬剤候補
・主要企業情報

What is holding you back in the Antisense Oligonucleotide Therapeutics Business?

Antisense Oligonucleotide Therapeutics has great potential to target specific genes of interest in the context of precision medicine. Optimization of enhanced delivery, specificity, affinity, and nuclease resistance with reduced toxicity is underway in different disease context. This report gives a complete overview of antisense therapy and highlights its potential.

Our 360+ page report provides 275 tables, 191 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing antisense oligonucleotide therapeutics market. Buy our report to see how to exploit these opportunities in the global market.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

Discover sales predictions for the global antisense oligonucleotide therapeutics market and submarkets

Over the last few years, the antisense oligonucleotide therapeutics has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body. Along with revenue prediction for the overall world market, there are 5 segmentations of the antisense oligonucleotide therapeutics market, with forecasts for 5 Therapeutic Area, 6 Route of Administration, 4 Types, each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Leading companies and the potential for market growth

As per Visiongain analysis, global antisense oligonucleotide therapeutics market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

What Segments Are Covered in the Report?

Global Antisense Oligonucleotide Therapeutics Market by Therapeutic Area (COVID-19 Impact Recovery Analysis Covered)
• Genetic Disorders
• Neurological Disorders
• Oncological Disorders
• Metabolic Disorders
• Ophthalmic Disorders
• Other Therapeutic Areas
Global Antisense Oligonucleotide Therapeutics Market by Route of Administration (COVID-19 Impact Recovery Analysis Covered)
• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Topical Delivery
• Other Delivery Methods
Global Antisense Oligonucleotide Therapeutics Market by Type (COVID-19 Impact Recovery Analysis Covered)
• Ribozyme
• DNAzyme
• Anti-Gene
• Other Type
Global Antisense Oligonucleotide Therapeutics Market by Region (COVID-19 Impact Recovery Analysis Covered)
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East
• Africa

Which Key Players Are Leading the Global Market and how much Share do they Hold?

The global market for antisense oligonucleotide therapeutics is ascending and has made significant gains in treatments. The players in the antisense oligonucleotide therapeutics market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:
• Mergers and acquisitions.
• Product launches.
• Collaborations and partnerships.
Product approval is a major milestone facing all key competitors in the antisense oligonucleotide therapeutics market. Several strategies were implemented by key market players between 2015 and Jan 2021. There are over 50+ pharma companies involved in different aspects of antisense oligonucleotide therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.

How the Antisense Oligonucleotide Therapeutics Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated
• What is the current size of the overall antisense oligonucleotide therapeutics market? How much will this market be worth from 2021 to 2031?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are some of the most prominent antisense oligonucleotide therapeutics currently in development?
• What are the main trends that will affect the world antisense oligonucleotide therapeutics market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global antisense oligonucleotide therapeutics market evolve over the forecasted period, 2021 to 2031?
• Which therapies can succeed and what revenues could they generate to 2031?
• What will be the main commercial drivers for the antisense oligonucleotide therapeutics market from 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
• How will that industry evolve between 2021 and 2031, especially in R&D?
Top 10 Leading Players Profiled in the Report
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Biogen Inc.
• Alnylam Pharmaceuticals, Inc.
• Antisense Therapeutics Limited (ANP)
• Arrowhead Pharmaceuticals, Inc.,
• Enzon Pharmaceuticals, Inc.
• Bio-Path Holdings, Inc.
• GlaxoSmithKline PLC
• Geron Corporation (Geron)
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

*** レポート目次(コンテンツ)***

1 Report Overview
1.1 Global Antisense Oligonucleotide Therapeutics Market Overview
1.2 Study Goals and Objectives
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Primary Research
1.7.2 Secondary Research
1.7.3 Data Sources
1.8 Market Evaluation & Forecasting Methodology
1.9 COIVD-19 Impact Recovery Pattern Analysis
1.9.1 V-Shaped Recovery
1.9.2 U-Shaped Recovery
1.9.3 W-Shaped Recovery
1.9.4 L-Shaped Recovery
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2 Executive Summary
2.1 Chemical modifications of antisense oligonucleotides (ASO)
3 Antisense Oligonucleotide Therapeutics Products and Technology Overview
3.1 Introduction to Nucleic Acid Technologies
3.2 Genetic Variation and Analysis
3.2.1 Sequencing Technologies
3.2.2 Sanger Sequencing
3.3 Next-generation Sequencing
3.3.1 DNA Write (Synthesis) Technologies
3.4 PCR-Based Approaches
3.5 Solid-Phase-Based Approaches
3.5.1 Microfluidic Technologies
3.5.2 DNA Microarrays
3.6 Gene Editing Technologies
3.7 CRISPR Enzyme Technologies
3.8 Gene Editing Delivery Technologies
3.9 Viral Delivery Technologies
4 DNA Read, Write and Edit Initiatives
4.1 Initiatives
4.2 American Gut Consortium
4.2.1 BabySeq
4.2.2 Blood Profiling Atlas
4.2.3 Cancer-ID
4.2.4 Cancer Moon Shots Program
4.2.5 China Precision Medicine Initiative
4.2.6 Clinical Genome Resource
4.2.7 Epigenetics for Females Personalized Cancer Care
4.2.8 France Genomic Medicine Plan
4.2.9 Friends of Cancer Research Project
4.3 Gene Therapy Initiative
4.3.1 Immunomonitor Consortium
4.3.2 Integration of Imaging and Fluid-based Tumor Monitoring in Cancer Therapy Program
4.3.3 Laboratory for Genomics Research
4.3.4 Lung Cancer Master Protocol Project
4.3.5 Matchmaker Exchange
4.3.6 Medical Genome Initiative
4.3.7 Million Veteran Program
4.3.8 Molecular Integration in Neurological Diagnosis
4.3.9 MedSeq
4.4 National Microbiome Initiative
4.4.1 Next-generation Single Cell Analysis Program
4.4.2 Precision Medicine Initiative
4.4.3 Prospective Registry of Multiple Testing
4.4.4 Quality Assurance Initiative Pathology Project
4.4.5 Somatic Cell Genome Editing Program
4.4.6 Trans Omics for Precision Medicine Initiative
4.4.7 Population Sequencing Programs
5 Market Dynamics
5.1 Overview
5.2 SWOT Analysis
5.3 Drivers of Antisense Oligonucleotide Therapeutics Market
5.3.1 High Unmet Medical Need
5.3.2 Positive Investment Environment
5.3.3 Strong Pipeline
5.3.4 Acceptance from Regulatory Authorities
5.4 Challenges for Antisense Oligonucleotide Therapeutics Market
5.4.1 Lack of Regulatory Guidance
5.4.2 Need for Skilled Labor
5.5 Opportunities for Antisense Oligonucleotide Therapeutics Market
5.5.1 Emerging Markets
5.5.2 Development of Better Diagnostic Methods
5.5.3 Acquisitions and Partnerships
5.6 Threats to the Antisense Oligonucleotide Therapeutics Market
5.6.1 New Government Regulations
5.6.2 Stiff Competition in the Global Market
5.7 Porter’s Five Forces Analysis of the Antisense Oligonucleotide Therapeutics Market
5.7.1 Bargaining Power Of Suppliers-Low
5.7.2 Bargaining Power of Buyers-High
5.7.3 Intensity of Competition-High
5.7.4 Threat of Substitute Products-High
5.7.5 Threat of New Entrants-High
6 Global Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
6.1 Global Market Outlook
6.1.1 FDA Approved Formulations
6.2 Global Market Size Estimation and Forecast
6.2.1 Pre-COVID-19 Market Analysis
6.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
6.3 Global Market Breakdown by Region
6.3.1 Pre-COVID-19 Market Analysis
6.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
6.4 Global Market Breakdown by Therapeutic Area
6.4.1 Antisense Oligonucleotide Based Therapy in Neuromuscular Disorders
6.4.2 Pre-COVID-19 Market Analysis
6.4.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
6.5 Global Market Breakdown by Route of Administration
6.5.1 Enhanced Stabilization Chemistry-Based Delivery
6.5.2 Nanoformulation-Based Delivery
6.5.3 Lipid-Based Delivery Systems
6.5.4 Pre-COVID-19 Market Analysis
6.5.5 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
6.6 Global Market Breakdown by Type
6.6.1 Antisense Therapy For Cancer
6.6.2 Antisense Therapy For Cardiovascular Diseases
6.6.3 Antisense Therapy For Inflammation And Autoimmune Diseases
6.6.4 Antisense Therapy In Neurological Disorders
6.6.5 Antisense Therapy For Infectious Diseases
6.6.6 Pre-COVID-19 Market Analysis
6.6.7 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7 North America Antisense Oligonucleotide Therapeutics Market Outlook
7.1 North America Market Overview
7.2 North America Market Size Estimation and Forecast
7.2.1 Pre-COVID-19 Market Analysis
7.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.3 North America Market Breakdown by Country
7.3.1 Pre-COVID-19 Market Analysis
7.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.4 North America Market Breakdown by Therapeutic Area
7.4.1 Pre-COVID-19 Market Analysis
7.4.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.5 North America Market Breakdwon by Route of Administration
7.5.1 Pre-COVID-19 Market Analysis
7.5.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.6 North America Market Breakdown by Type
7.6.1 Pre-COVID-19 Market Analysis
7.6.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.7 US Antisense Oligonucleotide Therapeutics Market Outlook
7.7.1 Country Market Overview
7.7.2 Pre-COVID-19 Market Analysis
7.7.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.8 Canada Antisense Oligonucleotide Therapeutics Market Outlook
7.8.1 Country Market Overivew
7.8.2 Pre-COVID-19 Market Analysis
7.8.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8 Europe Antisense Oligonucleotide Therapeutics Market Outlook
8.1 Europe Market Overview
8.2 Europe Market Size Estimation and Forecast
8.2.1 Pre-COVID-19 Market Analysis
8.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.3 Europe Market Breakdown by Country
8.3.1 Pre-COVID-19 Market Analysis
8.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.4 Europe Market Breakdown by Therapeutic Area
8.4.1 Pre-COVID-19 Market Analysis
8.4.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.5 Europe Market Breakdwon by Route of Administration
8.5.1 Pre-COVID-19 Market Analysis
8.5.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.6 Europe Market Breakdown by Type
8.6.1 Pre-COVID-19 Market Analysis
8.6.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.7 Germany Antisense Oligonucleotide Therapeutics Market Outlook
8.7.1 Country Overview
8.7.2 Pre-COVID-19 Market Analysis
8.7.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.8 UK Antisense Oligonucleotide Therapeutics Market Outlook
8.8.1 Country Market Overview
8.8.2 Pre-COVID-19 Market Analysis
8.8.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.9 France Antisense Oligonucleotide Therapeutics Market Outlook
8.9.1 Country Market Overview
8.9.2 Pre-COVID-19 Market Analysis
8.9.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.10 Italy Antisense Oligonucleotide Therapeutics Market Outlook
8.10.1 Country Market Overview
8.10.2 Pre-COVID-19 Market Analysis
8.10.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.11 Spain Antisense Oligonucleotide Therapeutics Market Outlook
8.11.1 Country Market Overview
8.11.2 Pre-COVID-19 Market Analysis
8.11.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.12 Rest of Europe Antisense Oligonucleotide Therapeutics Market Outlook
8.12.1 Pre-COVID-19 Market Analysis
8.12.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9 Asia-Pacific Antisense Oligonucleotide Therapeutics Market Outlook
9.1 Asia-Pacific Market Overview
9.2 Asia-Pacific Market Size Estimation and Forecast
9.2.1 Pre-COVID-19 Market Analysis
9.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.3 Asia-Pacific Market Breakdown by Country
9.3.1 Pre-COVID-19 Market Analysis
9.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.4 Asia-Pacific Market Breakdown by Therapeutic Area
9.4.1 Pre-COVID-19 Market Analysis
9.4.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.5 Asia-Pacific Market Breakdwon by Route of Administration
9.5.1 Pre-COVID-19 Market Analysis
9.5.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.6 Asia-Pacific Market Breakdown by Type
9.6.1 Pre-COVID-19 Market Analysis
9.6.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.7 China Antisense Oligonucleotide Therapeutics Market Outlook
9.7.1 Country Market Overview
9.7.2 Pre-COVID-19 Market Analysis
9.7.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.8 India Antisense Oligonucleotide Therapeutics Market Outlook
9.8.1 Country Market Overview
9.8.2 Pre-COVID-19 Market Analysis
9.8.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.9 Japan Antisense Oligonucleotide Therapeutics Market Outlook
9.9.1 Country Market Overview
9.9.2 Pre-COVID-19 Market Analysis
9.9.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.10 South Korea Antisense Oligonucleotide Therapeutics Market Outlook
9.10.1 Country Market Overview
9.10.2 Pre-COVID-19 Market Analysis
9.10.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.11 Australia Antisense Oligonucleotide Therapeutics Market Outlook
9.11.1 Pre-COVID-19 Market Analysis
9.11.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.12 Rest of Asia-Pacific Antisense Oligonucleotide Therapeutics Market Outlook
9.12.1 Pre-COVID-19 Market Analysis
9.12.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10 Latin America, Middle East & Africa Antisense Oligonucleotide Therapeutics Market Outlook
10.1 LAMEA Market Overview
10.2 LAMEA Market Size Estimation and Forecast
10.2.1 Pre-COVID-19 Market Analysis
10.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.3 LAMEA Market Breakdown by Country
10.3.1 Pre-COVID-19 Market Analysis
10.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.4 LAMEA Market Breakdown by Therapeutic Area
10.4.1 Pre-COVID-19 Market Analysis
10.4.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.5 LAMEA Market Breakdwon by Route of Administration
10.5.1 Pre-COVID-19 Market Analysis
10.5.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.6 LAMEA Market Breakdown by Type
10.6.1 Pre-COVID-19 Market Analysis
10.6.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.7 Brazil Antisense Oligonucleotide Therapeutics Market Outlook
10.7.1 Country Market Overview
10.7.2 Pre-COVID-19 Market Analysis
10.7.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.8 Saudi Arabia Antisense Oligonucleotide Therapeutics Market Outlook
10.8.1 Country Market Overview
10.8.2 Pre-COVID-19 Market Analysis
10.8.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.9 South Africa Antisense Oligonucleotide Therapeutics Market Outlook
10.9.1 Country Market Overview
10.9.2 Pre-COVID-19 Market Analysis
10.9.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.10 Mexico Antisense Oligonucleotide Therapeutics Market Outlook
10.10.1 Country Market Overview
10.10.2 Pre-COVID-19 Market Analysis
10.10.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.11 UAE Antisense Oligonucleotide Therapeutics Market Outlook
10.11.1 Country Market Overview
10.11.2 Pre-COVID-19 Market Analysis
10.11.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.12 Rest of LAMEA Antisense Oligonucleotide Therapeutics Market Outlook
10.12.1 Market Overview
10.12.2 Pre-COVID-19 Market Analysis
10.12.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
11 Potential Drug Candidates in Clinical Trials
11.1 Tominersen
12 Leading Company Profiles
12.1 Ionis Pharmaceuticals, Inc
12.1.1 Company Snapshot
12.1.2 Company Overview
12.1.3 Company Financial Profile
12.1.4 Company Product Benchmarking
12.1.5 Company Recent Developments
12.2 Sarpeta Therapeutics Inc.
12.2.1 Company Snapshot
12.2.2 Company Overview
12.2.3 Company Financial Profile
12.2.4 Company Product Benchmarking
12.2.5 Company Recent Developments
12.3 Biogen Inc
12.3.1 Company Snapshot
12.3.2 Company Overview
12.3.3 Company Financial Profile
12.3.4 Company Product Benchmarking
12.3.5 Company Recent Developments
12.4 Alnylam Pharmaceuticals, Inc
12.4.1 Company Snapshot
12.4.2 Company Overview
12.4.3 Company Financial Profile
12.4.4 Company Product Benchmarking
12.4.5 Company Recent Developments
12.5 Antisense Therapeutics Limited
12.5.1 Company Snapshot
12.5.2 Company Overview
12.5.3 Company Financial Profile
12.5.4 Company Product Benchmarking
12.5.5 Company Recent Developments
12.6 Arrowhead Pharmaceuticals Inc.
12.6.1 Company Snapshot
12.6.2 Company Overview
12.6.3 Company Financial Profile
12.6.4 Company Product Benchmarking
12.6.5 Company Recent Developments
12.7 Enzon Pharmaceuticals, Inc.
12.7.1 Company Snapshot
12.7.2 Company Overview
12.7.3 Company Financial Profile
12.7.4 Company Product Benchmarking
12.7.5 Company Recent Developments
12.8 Bio-Path Holdings, Inc.
12.8.1 Company Snapshot
12.8.2 Company Overview
12.8.3 Company Financial Profile
12.8.4 Company Product Benchmarking
12.8.5 Company Recent Developments
12.9 GlaxoSmithKline PLC
12.9.1 Company Snapshot
12.9.2 Company Overview
12.9.3 Company Financial Profile
12.9.4 Company Product Benchmarking
12.9.5 Company Recent Developments
12.10 Geron Corporation (Geron)
12.10.1 Company Snapshot
12.10.2 Company Overview
12.10.3 Company Financial Profile
12.10.4 Company Product Benchmarking
12.10.5 Company Recent Developments
13 Conclusion & Recommendations
13.1 Recommendations
14 Glossary



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(VGA21MA007 )"世界のアンチセンスオリゴヌクレオチド(ASO)治療市場2021-2031" (英文:Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031)はvisiongain社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。